Clinical trial
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two…
NCT00310596 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00310596 |
|---|---|
| Title | Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects |
| Official title | Cardiovascular Safety Study of 0.1 and 0.3 mmol/kg Magnevist® Injection at Two Injection Rates (Bolus and 10 mL/15 Sec.) in Normal Subjects Following a Randomized, Cross-over Design Using Placebo and a Concurrent Positive Control |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo |
| Enrollment | 71 |
| Start date | Jan 1, 2004 |
| Completion | Mar 1, 2004 |
| First posted | Apr 4, 2006 |
| Last update posted | Dec 30, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: